Воплощение идеи вторичной профилактики коронарной болезни сердца в реальной практике
Аннотация
Статья посвящена обзору по проблеме отношения практических врачей к выполнению программ вторичной профилактики коронарной болезни сердца. На примере крупных клинических трайлов показано, что в большинстве стран происходят позитивные изменения в выполнении мер по вторичной профилактике. В работах о выполнении программ вторичной профилактики в России имеет место несоответствие практики мировым стандартам. В частности, российские врачи используют низкие дозы препаратов стратегического назначения, редко (17%) рекомендуют пациентам гиполипидемическую терапию.
Об авторах
Д. М. Аронов
Государственный научно-исследовательский центр профилактической медицины Росздрава, Москва
Россия
Россия
О. Ю. Соколова
Государственный научно-исследовательский центр профилактической медицины Росздрава, Москва
Россия
Россия
Л. А. Гутковская
Государственный научно-исследовательский центр профилактической медицины Росздрава, Москва
Россия
Россия
Список литературы
1. Albright CL, Cohen S, Gibbons L, et al. Incorporating physical activity advice into primary care: physician-delivered advice within the activity counseling trial. Am J Prev Med 2000; 18(3): 225-34.
2. Anda R, Remington PL, Sienko DG, Davis RM. Are physicians advising smokers to quit? The patient’s perspective. JAMA 1987; 257(14): 1916-9.
3. Ansari M, Alexander M, Tutar A, et al. Cardiology participation improves outcomes in patients with new-onset heart failure in the outpatient setting. JACC 2003; 41(1): 62-8.
4. Baberg HT, Yazar A, Brechmann T, et al. Health care quality: medication and prevention in patients with and without coronary heart disease. Med Klin (Munich) 2004; 99(1): 1-6.
5. Balk SJ, Landesman LY, Spellmann M. Centers for disease control and prevention lead guidelines: do pediatricians know them? J Pediatr 1997; 131 (2): 325-7.
6. Barron HV, Michaels AD, Maynard C, Every NR. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. JACC 1998; 32(2): 360-7.
7. Becker RC, Burns M, Gore JM, et al. Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States. J Thromb Thrombolysis 2000; 9(3): 207-15.
8. Bjerrum L, Larsen J, Kragstrup J. Increased use of lipid-lowering agents after implementation of clinical guidelines in general practice. Ugeskr Laeger 2003; 165(2): 120-3.
9. Black JS, Sefcik T, Kapoor W. Health promotion and disease prevention in the elderly. Comparison of house staff and attending physician attitudes and practices. Arch Intern Med 1990; 150(2): 389-93.
10. Boissel JP, Nemoz C, Gillet J, et al. Drug prescription in myocardial postinfarction: results of the EPPI (etude de prescription postinfarctus). A French cooperative study. Arch Mal Coer Vaiss 1990; 83(12): 1777-82.
11. Boissel JP, Nemoz C, Leizorovicz A, Gillet J. Drug prescription evaluation in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study. Arch Mal Coeur Vaiss 1995; 88(9): 1261-6.
12. Bradley KA, Curry SJ, Koepsell TD, Larson EB. Primary and secondary prevention of alcohol problems: U.S. internist attitudes and practices J Gen Intern Med 1995; 10(2): 67-72.
13. Bradshaw PJ, Jamrozik K, Gilfillan I, Thompson PL. Preventing recurrent events long term after coronary artery bypass graft: suboptimal use of medications in a population study. Am Heart J 2004; 147(6): 1047-53.
14. Brotons C, Calvo F, Cascant P, et al. Is prophylactic treatment after myocardial infarction evidence-based? Fam Pract 1998; 15(5): 457-61.
15. Bull FC, Schipper EC, Jamrozik K, Blanksby BA. How can and do Australian doctors promote physical activity? Prev Med 1997; 26(6): 866-73.
16. Carrabba N, Barchielli A, Santoro GM, et al. Treatment and outcome in an unselected elderly population with acute myocardial infarction: 6-month follow-up results. Eur Heart J 2002; 4 (Abstr. Suppl. ): 502.
17. Chen J, Radford MJ, Wang Y, Krumholz HM. Care and out comes of elderly patients with acute myocardial infarction by physician specialty: the effects of comorbidity and functional limitations. Am J Med 2000; 108: 460-9.
18. Cheng TL, Miller EB, Ottolini M, et al. Tuberculosis testing. Physician attitudes and practice. Arch Pediatr Adolesc Med 1996; 150(7): 682-5.
19. Crain EF, Weiss KB, Fagan MJ. Pediatric asthma care in US emergency departments. Current practice in the context of the National Institutes of Health guidelines. Arch Pediatr Adolesc Med 1995; 149(8): 893-901.
20. De Velasco JA, Cosin J, Lopez-Sendon JL, et al. La prevencion secundaria del infarcto de myocardio en Espana: estudio PREVESE. Rev Esp Cardiol 1997; 50: 406-15.
21. de Velasco JA, Cosin J, Lopez-Sendon JL, et al. Nuevos datos sobre la prevencion secundaria del infarto de miocardio en Espana. Resultados del estudio PREVESE II. Rev Esp Cardiol 2002; 55: 801-9.
22. Ergin A, Abaci A, Sakalli A, et al. Pharmacological profile of survivors of acute myocardial infarction at Turkisch academic hospitals. Int J Cardiol 1999; 68(3): 309-16.
23. EUROASPIRE I and II Group. Clinical realty of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
24. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.
25. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. Eur Heart J 1997; 18: 1569-82.
26. Ferguson SC, Lieu TA. Blood lead testing by pediatricians: practice, attitudes, and demographics. Am J Public Health 1997; 87(8): 1349-51.
27. Ferrier BM, Woodward CA, Cohen M, Williams AP. Clinical practice guidelines. New-to-practice family physicians’ attitudes. Can Fam Physician 1996; 42: 463-8.
28. Fischer M, Bassler A, Hengstenberg C, et al. ACE inhibition prescription in patients with myocardial infarct and ventricular dysfunction: inappropriate application of therapy standards in patient samples. Z Kardiol 2001; 90(2): 104-10.
29. Frieden TR, Mostashari F, Kerker BD, et al. Adult Tobacco Use Levels After Intensive Tobacco Control Measures: New York City, 2002-2003. Am J Public Health 2005; 95(6): 1016-23.
30. Frilling B, Schiele R, Gitt AK, et al. Maximal Individual Therapy in Acute Myocardial Infarction Study Group. Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study. Am Heart J 2004; 148(2): 306-11.
31. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician non-compliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) guidelines. Circulation 1998; 98(9): 851-5.
32. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients With Chronic Stable Angina). www.acc.org
33. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 1999; 33: 2092-7.
34. Gill JM, Diamond JJ, Leone FT, et al. Do physicians in Delaware follow national guidelines for tobacco counseling? Del Med J 2004; 76(8): 297-308.
35. Gitt AK, Wienbergen H, Schiele R, et al. Improvement in acute treatment of myocardial infarction in clinical practice 1994-2001 resulted in a 28% reduction of hospital mortality. Eur Heart J 2002; 4 (Abstr. Suppl.): 401.
36. Glanz K, Tziraki C, Albright CL, Fernandes J. Nutrition assessment and counseling practices: attitudes and interests of primary care physicians. J Gen Intern Med 1995; 10(2): 89-92.
37. Go AS, Rao RK, Dauterman KW, Massie BM. A systematic review of the effects of physician specialty on the treatment of coronary heart disease and heart failure in the United States. Am J Med 2000; 108: 216-26.
38. Graille V, Ferrieres J, Marques-Vidal P, et al. Long-term effects od prescription drugs in 174 patients treated for myocardial infarction, followed up from 4 to 5 years (the DEVENIR study). Arch Mal Coer Vaiss 1996; 89(1): 35-9.
39. Grilli R, Lomas J. Evaluating the message: the relationship between compliance rate and the subject of a practice guideline. Med Care 1994; 32: 202-13.
40. Harder S, Mohr O, Klepzig H. Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic. Int J Clin Pharmacol Ther 2001; 39(12): 534-8.
41. Harder S, Thurmann P, Thierolf C, Klepzig H. Prescription of cardiovascular drugs in outpatient care: a survey of outpatients in a German university hospital. Int J Clin Pharmacol Ther 1998; 36(4): 195-201.
42. Hayward RSA. Clinical practice guidelines on trial. CMAJ 1997; 156: 1725-7.
43. Hiddink GJ, Hautvast JG, van Woerkum CM, et al. Nutrition guidance by primary-care physicians: perceived barriers and low involvement. Eur J Clin Nutr 1995; 49(11): 842-51.
44. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19(6): 596-604.
45. Hyman DJ, Maibach EW, Flora JA, Fortmann SP. Cholesterol treatment practices of primary care physicians. Public Health Rep 1992; 107(4): 441-8.
46. Jollis JG, DeLong ER, Peterson ED, et al. Outcome of acute myocardial infarction according to the specialty of the admitting physician. New Engl J Med 1996; 335: 1880-7.
47. Kaplan CP, Perez-Stable EJ, et al. Smoking cessation counseling with young patients: the practices of family physicians and pediatricians. Arch Pediatr Adolesc Med 2004; 158(1): 83-90.
48. Klabunde CN, O’Malley MS, Kaluzny AD. Physicians’ reactions to change in recommendations for mammography screening. Am J Prev Med 1997; 13(6): 432-8.
49. Koelling TM, Eagle KA. Measuring the quality of outpatient cardiovascular care. JACC 2003; 41(1): 69-72.
50. Larsen J, Andersen M, Bjerrum L, et al. Insufficient use of lipid-lowering drugs and measurement of serum cholesterol among patients with a history of myocardial infarction. J Cardiovasc Risk 2003; 10(1): 61-4.
51. Lim LL, Tesfay GM, Heller RF. Management of patients with diabetes after heart attack: a population-based study of 1982 patients from a heart disease register. Aust N Z J Med 1998; 28(3): 334-42.
52. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14(12): 711-7.
53. Martinez M, Agusti A, Arnau JM, et al. Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period. Eur J Clin Pharmacol 1998; 54(3): 203-8.
54. McIlvain HE, Crabtree BF, Gilbert C, et al. Current trends in tobacco prevention and cessation in Nebraska physicians’ offices. J Fam Pract 1997; 44(2): 193-202.
55. Mehta RH, Montoye CK, Faul J, et al. American College of Cardiology Guidelines Applied in Practice Steering Committee. Enhancing quality of care for acute myocardial infarction: shifting the focus of improvement from key indicators to process of care and tool use; The American College of Cardiology Acute Myocardial Infarction Guidelines Applied in Practice Project in Michigan: Flint and Saginaw Expansion. JACC 2004; 43(12): 2166-73.
56. Mendelson G, Aronow WS. Underutilization of beta-blockers in older patients with prior myocardial infarction or coronary artery disease in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1997; 45(11): 1360-1.
57. Mitra S, Findley K, Frohnapple D, Mehta JL. Trends in the long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. Clin Cardiol 2002; 25(1): 16-8.
58. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111(4): 499-510.
59. Muniz GJ, Gomez DJJ, Santiago PMI, et al. Effect of a simple educational program for physicians on adherence to secondary prevention measures after discharge following acute coronary syndrome. The CAM Project. Rev Esp Cardiol 2004; 57(11): 1017-28.
60. National Center for Health Statistics. Report of final mortality statistics, 1995. Hyattsville, MD. Public Health Service; 1997 Monthly vital statistics report. Vol 45, no. 11.
61. Nicholis SJ, McElduff P, Dobson AJ, et al. Underuse of beta-blockers following myocardial infarction: tale of two cities. Intern Med J 2001; 31(7): 391-6.
62. Parker JO. Chronic Angina Pectoris: Inadequacies of Current Therapy. Am J Geriatr Cardiol 2004; 13(5): 261.
63. Pearson TA. The undertreatment of LDL-cholesterol: adressing the challenge. Int J Cardiol 2000; 74(Suppl 1): S23-8.
64. Rallidis LS, Zollindaki MG, Chatziioakomodis VK, et al. High prevalence and suboptimal treatment of risk factors in Greek coronary patients. Acta Cardiol 2001; 56(1): 7-15.
65. Report of Final Mortality Statistics 1995. Hyattsville, MD: National Center for Health Statistics; 1997. Advance data from Vital and Health Statistics, No. 11.
66. Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients in the 1990’s—their risk factors, stratification and survival in Canada: the Canadian Assessment of Myocardial Infarction (CAMI) Study. JACC 1996; 27: 1119-27.
67. Schocken DD, Schocken DM. Florida’s response to the Physician’s National Cholesterol Education Program. J Fla Med Assoc 1992; 79(2): 112-6.
68. Schucker B, Wittes JT, Santanello NC, et al. Change in cholesterol awareness and action. Results from national physician and public surveys. Arch Intern Med 1991; 151(4): 666-73.
69. Solberg LI, Brekke ML, Kottke TE. How important are clinician and nurse attitudes to the delivery of clinical preventive services? J Fam Pract 1997; 44(5): 451-61.
70. Soltesz KS, Price JH, Johnson LW, Tellijohann SK. Family physicians’ views of the preventive services task force recommendations regarding nutritional counseling. Arch Fam Med 1995; 4(7): 589-93.
71. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000; 101(10): 1097-101.
72. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. JACC 2003; 41(1): 56- 61.
73. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83(9): 1303-7.
74. Sueta CA, Massing MW, Chowdhury M, et al. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. J Card Fail 2003; 9(1): 36-41.
75. The American Heart Association. Biostatistical Fact Sheets. 1997; Dallas, TX: American Heart Association, 1–29.
76. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004; 255(4): 494-502.
77. Tran CT, Laupacis A, Mamdani MM, Tu JV. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J 2004; 148(5): 834-41.
78. Ujita K, Ohno K, Hashiguchi M, et al. Drug use evaluation of antidyslipidemic agents at a community hospital in Japan. Yakugaku Zasshi 2002; 122(7): 499-506.
79. Vikman S, Airaksinen JEK, Niemela K, FinACS group. Underuse of new treatment modalities in diabetics with non-ST- segment elevation acute coronary syndrome. Eur Heart J 2002; 4 (Abstr. Suppl.): 585.
80. Woolf SH. Practice guidelines: a new reality in medicine. III. Impact on patient care. Arch Intern Med 1993; 153(23): 2646-55.
81. Wright DJ, Grayson A, Jackson M, Dainty C. The reality of statin use in primary care! Eur Heart J 2002; 4(Abstr. Suppl.): 20.
82. Лепахин В.К., Фитилев С.Б., Титарова Ю.Ю. и др. Фармакотерапия стабильной стенокардии напряжения в Российской Федерации в 2001 г. Тезисы докладов. X Российский национальный конгресс «Человек и лекарство» 7-11 апреля 2003: 441.
83. Лепахин В.К., Астахова А.В, Фитилев С.Б. и др. Фармакобезопасность основных сердечно-сосудистых препаратов при стабильной стенокардии в Российской Федерации. Тезисы докладов. X Российский национальный конгресс «Человек и лекарство» 7-11 апреля 2003: 440.
84. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Факторы риска в популяции больных стабильной стенокардией напряжения в Российской Федерации в 2001 г. Тезисы докладов. X Российский национальный конгресс «Человек и лекарство» 7-11 апреля 2003; 442.
85. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP – Angina Treatment Pattern). Кардиология 2003; 5: 9-15.
86. Явелов И.С., Грацианский Н.А. Российский регистр острых коронарных синдромов: лечение и исходы в стационаре при остром коронарном синдроме без подъемов сегментов ST. Кардиология 2003; 12: 23-36.
87. Явелов И.С., Грацианский Н.А. Российский регистр острых коронарных синдромов: лечение и исходы в стационаре при остром коронарном синдроме с подъемами сегмента ST. Кардиология 2004; 4: 4-13.
Рецензия
Для цитирования:
Аронов Д.М., Соколова О.Ю., Гутковская Л.А. Воплощение идеи вторичной профилактики коронарной болезни сердца в реальной практике. Кардиоваскулярная терапия и профилактика. 2007;6(1):105-113.
For citation:
Aronov D.M., Sokolova O.Yu., Gutkovskaya L.A. Implementing principles of coronary heart disease secondary prevention into real-world clinical practice. Cardiovascular Therapy and Prevention. 2007;6(1):105-113. (In Russ.)
Просмотров:
491
Послать статью по эл. почте 
